BUFFALO, NY – August 29, 2025 – A new research paper was published in Volume 16 of Oncotarget on August 29, 2025, titled “In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma.”

An international team led by researchers at Lund University in Sweden has identified the molecular tools needed to reprogram ordinary cells into specialised immune cells. The discovery, published in Immunity, could pave the way for more precise and personalised cancer immunotherapies.

Gastric signet ring cell carcinoma (GSRCC) is a distinct subtype of gastric cancer (GC) with unique epidemiological and pathogenic characteristics. Despite its clinical significance, large-scale proteomic studies on GSRCC remain scarce, limiting our molecular understanding of the disease. Advanced mass spectrometry (MS)-based proteomics is crucial for identifying key biomarkers and drug targets, thereby enabling more effective therapeutic strategies.

Previously, research on controlling gene networks has been carried out based on a single stimulus-response of cells. More recently, studies have been proposed to precisely analyze complex gene networks to identify control targets. A KAIST research team has succeeded in developing a universal technology that identifies gene control targets in altered cellular gene networks and restores them. This achievement is expected to be widely applied to new anticancer therapies such as cancer reversibility, drug development, precision medicine, and reprogramming for cell therapy.

Cancer cells provide healthy neighbouring cells with additional cell powerhouses to put them to work. This has been demonstrated by researchers at ETH Zurich in a new study. In this way, cancer is exploiting a mechanism that frequently serves to repair damaged cells.

A research team led by Prof. GU Hongcang and ZHANG Fan from the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has identified a novel long non-coding RNA (lncRNA)-driven regulatory network that plays a central role in colorectal cancer (CRC) progression and immune response. 

Nearly 20 years ago, a man named Timothy Ray Brown who was living with HIV and cancer, underwent two courses of stem cell transplantation to treat his acute myeloid leukemia. By using donor cells that lacked a key molecule needed for HIV to enter and infect immune cells, the procedures not only led to remission of his cancer, but also cured him of HIV.